Table 5.
Effect of lung transplantation on HRQL by disease category
| Early change | Test of difference |
||
|---|---|---|---|
| SF12-PCS (MCID = 5) |
Group A (COPD) | 15.9 (11.5, 20.3) | P<0.001 |
| Group B (PAH) | 7.9 (1.0, 14.7) | ||
| Group C (CF) | 23.8 (19.5, 28.1) | ||
| Group D (PF) | 13.8 (11.9, 15.8) | ||
| SF12-MCS (MCID = 5) |
Group A (COPD) | 2.7 (−0.9, 6.4) | P=0.020 |
| Group B (PAH) | 0.1 (−5.6, 5.7) | ||
| Group C (CF) | 10.3 (6.4, 14.1) | ||
| Group D (PF) | 4.8 (3.1, 6.6) | ||
| AQ20-R (MCID = 1.75) |
Group A (COPD) | 7.7 (6.4, 9.1) | P=0.021 |
| Group B (PAH) | 4.5 (2.1, 6.9) | ||
| Group C (CF) | 9.4 (8.2, 10.6) | ||
| Group D (PF) | 7.9 (7.3, 8.6) | ||
| EQ5D (MCID = 0.06) |
Group A (COPD) | 0.15 (0.08, 0.21) | P=0.003 |
| Group B (PAH) | 0.07 (−0.05, 0.19) | ||
| Group C (CF) | 0.30 (0.22, 0.39) | ||
| Group D (PF) | 0.16 (0.13, 0.19) | ||
| EQVAS (MCID = 10) |
Group A (COPD) | 23.3 (16.2, 30.5) | P=0.003 |
| Group B (PAH) | 18.4 (2.6, 34.2) | ||
| Group C (CF) | 43.0 (36.8, 49.3) | ||
| Group D (PF) | 30.8 (27.4, 34.3) | ||
For Group A, n = 36, Group B, n = 8, Group C, n = 19, Group D, n = 148) Adjusted for sex, age group, baseline body mass index, forced expiratory volume in 1 second, six minute walk distance and Lung Allocation Score
Early: Average change from before to 3 months after transplant. Effect estimates reflect average change in HRQL over the early or late time period. COPD = Chronic Obstructive Pulmonary Disease; PAH = Pulmonary Arterial Hypertension; CF = Cystic Fibrosis; PF = Pulmonary Fibrosis; BMI = Body Mass Index; 6MWD = six-minute walk distance; FEV1 = forced expiratory capacity in 1 second; LAS = Lung Allocation Score; SF12-PCS = Medical Outcomes Study Short Form 12 Physical Component Summary scale; SF12-MCS = Medical Outcomes Study Short Form 12 Mental Component Summary scale; AQ20-R = Airway Questionnaire 20- Revised; score reversed for ease of interpretation); EQ5D = Euroqol 5D; EQVAS = Euroqol Visual Analog Scale